ExodusPoint Capital Management LP Invests $677,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

ExodusPoint Capital Management LP acquired a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 88,187 shares of the company’s stock, valued at approximately $677,000. ExodusPoint Capital Management LP owned about 0.24% of iTeos Therapeutics at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in ITOS. Charles Schwab Investment Management Inc. lifted its holdings in shares of iTeos Therapeutics by 3.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 222,135 shares of the company’s stock valued at $2,268,000 after purchasing an additional 8,397 shares in the last quarter. State Street Corp raised its position in shares of iTeos Therapeutics by 21.9% during the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company’s stock worth $12,000,000 after purchasing an additional 211,452 shares during the last quarter. Wellington Management Group LLP lifted its stake in iTeos Therapeutics by 20.9% in the 3rd quarter. Wellington Management Group LLP now owns 105,769 shares of the company’s stock valued at $1,080,000 after buying an additional 18,255 shares in the last quarter. XTX Topco Ltd acquired a new stake in iTeos Therapeutics during the 3rd quarter valued at $186,000. Finally, Geode Capital Management LLC increased its position in iTeos Therapeutics by 3.2% during the third quarter. Geode Capital Management LLC now owns 640,350 shares of the company’s stock worth $6,540,000 after buying an additional 20,092 shares in the last quarter. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on ITOS shares. JPMorgan Chase & Co. reduced their price objective on iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, March 6th. Wells Fargo & Company reduced their target price on shares of iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, March 6th. Wedbush reiterated an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Finally, HC Wainwright reissued a “buy” rating and set a $46.00 price objective on shares of iTeos Therapeutics in a research note on Thursday, March 6th.

iTeos Therapeutics Price Performance

NASDAQ ITOS opened at $5.65 on Friday. The company has a market cap of $215.80 million, a P/E ratio of -1.79 and a beta of 1.43. iTeos Therapeutics, Inc. has a 12 month low of $4.80 and a 12 month high of $18.75. The company has a 50-day moving average of $6.74 and a 200-day moving average of $7.83.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.13. As a group, equities research analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 EPS for the current year.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.